Tag Archives: gene therapy

AstraZeneca Teams Up with Cellectis to Accelerate Gene Therapy Development

(IN BRIEF) AstraZeneca has entered into a collaboration and investment agreement with biotech firm Cellectis to fast-track the development of cutting-edge therapeutics in areas such as oncology, immunology, and rare diseases. This partnership will leverage Cellectis’ gene editing technologies and … Read the full press release

Alexion and AstraZeneca Acquire Rare Disease Gene Therapy Portfolio from Pfizer for $1 Billion

(IN BRIEF) Alexion, in collaboration with AstraZeneca Rare Disease, has finalized an agreement to acquire a collection of preclinical rare disease gene therapy programs and related technologies from Pfizer Inc. This strategic move combines the expertise of Alexion and AstraZeneca … Read the full press release

AskBio Initiates Clinical Trial for Gene Therapy Targeting Limb-Girdle Muscular Dystrophy Type 2I/R9

(IN BRIEF) Asklepios BioPharmaceutical, Inc. (AskBio), a gene therapy company owned by Bayer AG, has begun the Phase 1/Phase 2 LION-CS101 clinical trial for patients with limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). The trial is evaluating AB-1003 (LION-101), an investigational … Read the full press release

Bayer and Acuitas Therapeutics Join Forces for Targeted Gene Editing Delivery

Not intended for U.S. and UK Media (IN BRIEF) Bayer AG has partnered with Acuitas Therapeutics, Inc. to enhance its gene therapy portfolio. Acuitas’ lipid nanoparticle (LNP) delivery technology will enable targeted and efficient delivery of gene editing RNA components … Read the full press release

EQT Private Equity gab die Übernahme von SPT Labtech von Battery Ventures für 650 Millionen GBP bekannt

(PRESSEMITTEILUNG) STOCKHOLM, 22-Jun-2022 — /EuropaWire/ — EQT AB, eine zweckorientierte globale Investmentgesellschaft, hat die Übernahme von SPT Labtech bekannt gegeben von Battery Ventures, einer globalen, technologieorientierten Investmentgesellschaft, für 650 Mio. GBP (~ 756 Mio. EUR). SPT Labtech ist ein britisches … Read the full press release

EQT Private Equity announced the acquisition of SPT Labtech from Battery Ventures for GBP 650 million

(PRESS RELEASE) STOCKHOLM, 22-Jun-2022 — /EuropaWire/ — EQT AB, a purpose-driven global investment organization, has announced the acquisition of SPT Labtech from Battery Ventures, a global, technology-focused investment firm, for GBP 650 million (~ EUR 756 million). SPT Labtech is … Read the full press release

Bayer to use Mammoth’s CRISPR systems for the development of vivo gene-editing therapies

Agreement strengthens Bayer’s new cell and gene therapy platform further / Supports Mammoth’s vision of unlocking the full potential of novel CRISPR systems / Mammoth to receive upfront payment of USD 40 million, and potential future milestone payments of more … Read the full press release

Spinal muscular atrophy: New data for Evrysdi will be presented by Roche at the World Muscle Society (WMS) Virtual Congress 20 – 24 September 2021

New data show pre-symptomatic babies with spinal muscular atrophy (SMA) treated with Evrysdi maintained the ability to swallow Evrysdi has demonstrated consistent clinically meaningful efficacy in adults, children, and babies two months and older and is now approved in 58 countries worldwide Further … Read the full press release

Kuehne+Nagel’s subsidiary QuickSTAT opens new control tower in Singapore for time-critical clinical trial logistics

(PRESS RELEASE) SINGAPORE, 22-Jul-2021 — /EuropaWire/ — Kuehne+Nagel, one of the world’s leading logistics companies, has announced that its subsidiary QuickSTAT has opened a new control tower and conditioning facility in Singapore. The investment is part of Kuehne+Nagel and QuickSTAT’s … Read the full press release

Associazione Veneta Lotta alla Talassemia (AVLT) and the UK Thalassaemia Society (UKTS) Clarification on European Regulatory Status of LENTIGLOBIN™

(PRESS RELEASE) LONDON, 27-Mar-2019 — /EuropaWire/ — The LentiGlobin application for Conditional Marketing Authorization (cMAA) at the EMA from bluebird bio is still in the process of being reviewed by CHMP during their 25-28 March 2019 meeting. An opinion for … Read the full press release

Researchers Start New Clinical Trial for the Treatment of Genetic Blindness

OXFORD, 22-Mar-2017 — /EuropaWire/ — Researchers have started a new gene therapy clinical trial to treat X-linked retinitis pigmentosa (XLRP), the most common cause of blindness in young people. Retinitis pigmentosa is currently untreatable and leads to a slow and irreversible … Read the full press release

The European Medicines Agency releases draft guideline on the development of gene therapies

EMA invites feedback on its new draft guideline LONDON, 22-5-2015 — /EuropaWire/ — The European Medicines Agency (EMA) has released a draft guideline on quality, non-clinical and clinical aspects of gene therapies for a three-month public consultation. The document aims … Read the full press release